Akari Therapeutics, Plc (AKTX)
NASDAQ: AKTX · Real-Time Price · USD
0.968
-0.022 (-2.20%)
Dec 27, 2024, 4:00 PM EST - Market closed
Akari Therapeutics, Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Selling, General & Admin | 9.2 | 11.36 | 13.53 | 8.08 | 9.16 | 8.22 | |
Research & Development | 8.25 | 5.45 | 9.56 | 9.13 | 8.82 | 8.74 | |
Operating Expenses | 17.44 | 16.81 | 23.09 | 17.21 | 17.98 | 16.96 | |
Operating Income | -17.44 | -16.81 | -23.09 | -17.21 | -17.98 | -16.96 | |
Interest Expense | -0.12 | - | - | - | - | - | |
Interest & Investment Income | 0.01 | 0.08 | 0.05 | 0.01 | 0.01 | 0.01 | |
Currency Exchange Gain (Loss) | 0.14 | 0.14 | 0.45 | -0.19 | 0.35 | -0.07 | |
Other Non Operating Income (Expenses) | 1.26 | 6.58 | 4.84 | -0.03 | 0.53 | 0.18 | |
EBT Excluding Unusual Items | -16.14 | -10.01 | -17.75 | -17.42 | -17.08 | -16.85 | |
Pretax Income | -20.16 | -10.01 | -17.75 | -17.42 | -17.08 | -16.85 | |
Net Income | -20.16 | -10.01 | -17.75 | -17.42 | -17.08 | -16.85 | |
Net Income to Common | -20.16 | -10.01 | -17.75 | -17.42 | -17.08 | -16.85 | |
Shares Outstanding (Basic) | 8 | 5 | 3 | 2 | 2 | 1 | |
Shares Outstanding (Diluted) | 8 | 5 | 3 | 2 | 2 | 1 | |
Shares Change (YoY) | 76.18% | 56.79% | 45.46% | 35.87% | 72.53% | 18.87% | |
EPS (Basic) | -2.46 | -2.04 | -5.69 | -8.12 | -10.81 | -18.40 | |
EPS (Diluted) | -2.46 | -2.04 | -5.69 | -8.12 | -20.00 | -18.40 | |
Free Cash Flow | -14.84 | -16.43 | -21.5 | -18.85 | -16.95 | -12.92 | |
Free Cash Flow Per Share | -1.81 | -3.36 | -6.89 | -8.78 | -10.73 | -14.11 | |
EBITDA | -17.43 | -16.8 | -23.08 | -17.21 | -17.97 | -16.94 | |
D&A For EBITDA | 0.01 | 0 | 0 | 0 | 0.01 | 0.02 | |
EBIT | -17.44 | -16.81 | -23.09 | -17.21 | -17.98 | -16.96 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.